High prevalence of the CYP2B6 516G→T(*6) variant and effect on the population pharmacokinetics of efavirenz in HIV/AIDS outpatients in Zimbabwe

PsN-Toolkit—A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM

Lars Lindbom, Pontus Pihlgren, E. Niclas Jonsson · Computer Methods and Programs in Biomedicine · 2005 · 1.1K citations

Life Sciences, Bioinformatics, Biostatistics +8

Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

Schlomo Staszewski, Javier O Morales-Ramirez, Karen T. Tashima et al. · New England Journal of Medicine · 1999 · 1K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

Catia Marzolini, Amalio Telenti, Laurent A. Décosterd et al. · AIDS · 2001 · 836 citations

Pharmacy, Pharmacokinetics, Pharmacology +16

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

David W. Haas, Heather J. Ribaudo, Richard B. Kim et al. · PubMed · 2004 · 629 citations

Medicine, Pharmacokinetics, Pharmacology +17

The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic Activity

Bryan A. Ward, J. Christopher Gorski, David R. Jones et al. · Journal of Pharmacology and Experimental Therapeutics · 2003 · 594 citations

Medicine, Pharmacokinetics, Pharmacology +17